Time to Benefit for Lung Cancer Screening: A Systematic Review and Survival Meta-Analysis.

Kim EE, Cenzer I, Graham FJ, Kang J, Lee SJ, Rustagi AS. Time to Benefit for Lung Cancer Screening: A Systematic Review and Survival Meta-Analysis. American journal of preventive medicine. 2025 May 28; 107736, DOI: 10.1016/j.amepre.2025.107736.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

INTRODUCTION: Lung cancer screening with low-dose computed tomography (LDCT) reduces lung cancer mortality in the long term but carries immediate risks. Guidelines recommend screening persons whose life expectancy exceeds the screening test''s time to benefit (TTB), defined as the time from screening initiation to first observed benefit. This study aimed to estimate the TTB for lung cancer screening to prevent lung cancer mortality. METHODS: Randomized controlled trials of lung cancer screening with LDCT were identified from two prior systematic reviews and an updated search to December 3, 2023. Studies that reported lung cancer mortality were included. For each study, independent Weibull survival curves were fitted and Markov chain Monte Carlo simulations were generated to estimate the absolute risk reduction at different time points. Time to benefit was determined as the time at which absolute risk reduction thresholds (ARR = 0.0005, 0.001, 0.002) were crossed. These estimates were pooled using a random-effects meta-analysis model. RESULTS: A total of eight randomized controlled trials comprising 88,526 participants were included. Enrollment age ranged from 50 to 70 years of age; follow-up duration ranged from 7.3 to 12.3 years. For every 1000 persons screened, 3.4 years (95% CI 2.2-5.1) passed before one death from lung cancer was prevented (ARR = 0.001). The time to prevent one lung cancer death per 2000 persons screened (ARR = 0.0005) was 2.2 years (95% CI 1.4-3.4); per 500 persons screened (ARR = 0.002), it was 5.2 years (95% CI 3.7-7.3). DISCUSSION: Lung cancer screening is most appropriate for older adults at high risk of lung cancer with a life expectancy greater than 3.4 years.